Schizophrenia Spectrum and Other Psychotic Disorders Clinical Trial
Official title:
Rituximab - Immunotherapy for Schizophrenia Spectrum Disorder in Adults: An Open Pilot Study
This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant schizophrenia spectrum disorder in an open trial.
Immunological factors may be determinants for some psychiatric disorders, thus immunomodulation may be helpful. Rituximab (antibodies against CD20, cluster of differentiation), a standard treatment for multiple sclerosis, is an anti-inflammatory drug, hitherto not tested for psychiatric disorders. The aim of this study is to investigate whether the psychiatric symptoms of treatment-resistant adult psychiatric patients, diagnosed with schizophrenia spectrum disorder (SSD), are significantly improved after treatment with rituximab. Our purpose is to implement recent insights from "Immunopsychiatry" to find efficacious, but still tolerable treatment for these patients. This is a single-site, 20-week, open pilot, add-on treatment as usual, trial, where the patients will be followed for 1 year. Rituximab will be administered with one single dose of 1000 mg. Investigators will analyse inflammatory and metabolic biomarkers in relation to the primary outcome, treatment response (defined as clinically relevant reduction in the validated measure PANSS). Other outcomes are "much" or "very much improved" on Clinical Global Impression - Improvement scale (CGI-I) and change in Personal and Social Performance Scale measuring overall disability. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
| Enrolling by invitation |
NCT03090490 -
10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
|
N/A | |
| Completed |
NCT03323437 -
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
|
Phase 4 | |
| Completed |
NCT06040944 -
Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
|
||
| Recruiting |
NCT04452175 -
Cigarette Consumption After switchinG to High or Low Nicotine strENght E-cigaretteS In Smokers With Schizophrenia
|
N/A | |
| Completed |
NCT03501888 -
Cognitive Behavior Therapy for Patients With Psychoses.
|
N/A | |
| Completed |
NCT05601063 -
Ascertaining Diagnosis Classification With Elicited Speech
|
||
| Recruiting |
NCT05877716 -
EPI-MINN: Targeting Cognition and Motivation - National
|
N/A | |
| Completed |
NCT03955549 -
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
|
Phase 3 | |
| Completed |
NCT03235908 -
Copeptin in Outcome Prediction of an Acute Psychotic Episode
|
||
| Recruiting |
NCT05622201 -
A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults
|
Phase 2 | |
| Recruiting |
NCT05491486 -
Mindfulness, Empathy and the Oxytocinergic System in Persons With Schizophrenia
|
N/A | |
| Recruiting |
NCT04916496 -
Acceptance and Commitment Therapy-based Lifestyle Counselling Programme for Early Psychosis on Physical Activity
|
N/A | |
| Recruiting |
NCT04104347 -
Metacognitive Training and Insight in Schizophrenia
|
N/A | |
| Recruiting |
NCT05664594 -
State Representation in Early Psychosis - Project 4
|
N/A | |
| Recruiting |
NCT05538832 -
Remote State Representation in Early Psychosis
|
Early Phase 1 | |
| Completed |
NCT02220504 -
3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
|
N/A | |
| Completed |
NCT04665401 -
Personalizing Interventions Using Real-World Interactions
|
N/A | |
| Recruiting |
NCT03919760 -
Early Psychosis Intervention - Spreading Evidence-based Treatment
|